The Technical Analyst
Seelos Therapeutics Inc [SEEL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Seelos Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.89% $0.291
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.98 mill |
| EPS: | -7.73 |
| P/E: | -0.0400 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 13.68 mill |
| Avg Daily Volume: | 0.441 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0400 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0400 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.186 - 0.396 ( +/- 36.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-29 | Golembiewski Michael Joseph | Buy | 417 | Common Stock |
| 2024-01-12 | Mehra Raj | Buy | 70 383 | Stock Option (right to buy) |
| 2024-01-12 | Golembiewski Michael Joseph | Buy | 24 537 | Stock Option (right to buy) |
| 2024-01-04 | Pascoe Richard W | Buy | 1 666 | Stock Option (right to buy) |
| 2024-01-04 | Dalesandro Margaret | Buy | 1 666 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 92 transactions |
| Buy: 14 639 227 | Sell: 4 987 490 |
Forecast:
16:00 - $0.287
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.287
Forecast 2: 16:00 - $0.287
Forecast 3: 16:00 - $0.287
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.291 (1.89% ) |
| Volume | 0.557 mill |
| Avg. Vol. | 0.441 mill |
| % of Avg. Vol | 126.30 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SEEL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SEEL
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-03-19 08:15:00 - Press Release
Seelos Therapeutics Provides Update On Top-line Results From Its Amyotrophic Lateral Sclerosis (als) Study With Sls-005 (iv Trehalose)
New york, march 19, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the phase 2/3 healey als platform trial. this study was performed in collaboration with the sean m.
2024-01-26 08:30:00 - Press Release
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering And Concurrent Private Placement Priced At-the-market Under Nasdaq Rules
New york , jan. 26, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) (the "company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ("cns") and rare diseases, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 3,404,256 shares of its common stock in a registered direct offering and unregistered common warrants exercisable for up to an aggregate of 3,404,256 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering") at a combined purchase price of $1.175 per share and accompanying common warrant priced at-the-market under nasdaq rules...
2024-01-22 08:00:00 - Press Release
Seelos Therapeutics Announces Receipt Of Minutes From Its End Of Phase Ii Meeting With The United States Food And Drug Administration (fda) Highlighting Modifications To The Primary And Secondary Endpoints Of Its Phase Ii Study Of Sls-002
Company plans to continue its previously announced potential partnership discussions and expects to proceed to phase iii with sls-002 in adults with major depressive disorder (mdd) at imminent risk of suicide new york , jan. 22, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the receipt of minutes from its end of phase ii meeting with the fda. in the meeting minutes, the fda agreed that the primary endpoint in a phase iii trial could be the change from baseline in the montgomery-Åsberg depression rating scale (madrs) total score at day 16, rather than the 24-hour timepoint that was selected in the phase ii sls-002-201 study.
2024-01-02 08:00:00 - Press Release
Leading Independent Proxy Advisory Firm Iss Recommends Seelos Stockholders Vote "for" All Proxy Proposals At The Special Meeting To Be Held On January 10, 2024
New york, jan. 2, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that institutional shareholder services ("iss"), a leading independent proxy voting and corporate governance advisory firm, recommends seelos stockholders vote "for" all proposals at the special meeting of stockholders, including management's proposal to increase the number of authorized shares of common stock. the special meeting is scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/seel2024sm, on wednesday, january 10, 2024 at 8:00 a...
2023-12-22 08:00:00 - Press Release
Seelos Therapeutics, Inc. Releases Letter To Its Stockholders
New york , dec. 22, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released a letter to its stockholders from raj mehra, ph.d., chairman and chief executive officer of seelos, the text of which is copied below.
Latest News
2024-01-09 13:56:16 - InvestorPlace
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine as a depression therapeutic.
2023-11-29 10:38:55 - InvestorPlace
Why Are Stocks Up Today?
Stocks are up today as investors react to the latest comments from members of the Federal Reserve. The most important of these comes from Fed Governor Christopher Waller.
2023-11-22 15:14:10 - PennyStocks
Penny Stocks To Buy Under $1? 3 For Your Holiday Watch List
Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 100% or more.
2023-10-27 08:11:00 - PRNewsWire
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis and Spinocerebellar ataxia NEW YORK , Oct. 27, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster from a study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in a tauopathy model of Alzheimer's disease at the Society for Neuroscience's Neuroscience 2023 meeting, to be held on November 11-15, 2023, at the Walter E...
2023-10-23 13:48:46 - PennyStocks
Best Penny Stocks This Week? 3 To Watch During Earnings Season
The process of buying penny stocks is similar to purchasing any other stock shares. The main difference is penny stocks are often not listed on major exchanges like the NYSE and Nasdaq.
2023-09-21 09:30:40 - InvestorPlace
Why Is Seelos Therapeutics (SEEL) Stock Down 25% Today?
Seelos Therapeutics (NASDAQ: SEEL ) stock is falling on Thursday after the company released results from a clinical trial. Seelos Therapeutics first reported results from its Phase 2 trial of SLS-002 on Wednesday.
2023-09-20 08:33:13 - Proactive Investors
Seelos tumbles 66% as depression drug fails after it recruits too few patients
Seelos Therapeutics (NASDAQ:SEEL) Inc's share price plummeted by 66% pre-market after the company announced that its phase II study for SLS-002, a treatment for adults with major depressive disorder at risk of suicide, failed to meet its primary goal. The primary goal, or "endpoint," is a key measure used to determine the success of a treatment in clinical trials.
2023-09-20 07:46:00 - Market Watch
Seelos Therapeutics' stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpoint
Seelos Therapeutics Inc.'s stock SEEL tumbled 36% in premarket trade Wednesday, after the company reported promising results from a trial of a treatment for Acute Suicidal Ideation and Behavior (ASIB) in adults with Major Depressive Disorder (MDD) but said a too-small sample size means the study did not meet its primary endpoint. Seelos enrolled 147 patients in the Phase 2 trial of SLS-002, intranasal racemic ketamine, below its target for 220 patients, which it blamed on financial constraints.
2023-09-06 20:17:22 - InvestorPlace
7 Biotech Stocks to Sell in September Before They Crash & Burn
Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.
2023-07-12 19:09:19 - Seeking Alpha
Seelos: 2 Catalysts Before End Of 2023 Make This A Must Watch
Results from Part 2 of the phase 2 registration-directed study, using SLS-002 for acute suicidal ideation and behavior for MDD, are expected to be released by Q3 of 2023. The major depressive disorder treatment market is expected to reach $14.96 billion by 2032; Even if only accounting for 58% of MDD patients this is still a huge market. Results from the phase II/III study, using SLS-005 for the treatment of patients with Amyotrophic lateral sclerosis, are expected to be released by Q4 of 2023.